215 related articles for article (PubMed ID: 30964601)
1. Continued administration of pembrolizumab for adenocarcinoma of the lung after the onset of fulminant type 1 diabetes mellitus as an immune-related adverse effect: A case report.
Edahiro R; Ishijima M; Kurebe H; Nishida K; Uenami T; Kanazu M; Akazawa Y; Yano Y; Mori M
Thorac Cancer; 2019 May; 10(5):1276-1279. PubMed ID: 30964601
[TBL] [Abstract][Full Text] [Related]
2. A case of pembrolizumab-induced fulminant Type 1 diabetes mellitus in breast cancer.
Tang Y; Zhao Z; Wang X; Zuo W; Zhang B; Yuan T; Fu Y
Immunotherapy; 2021 Apr; 13(6):483-489. PubMed ID: 33626915
[TBL] [Abstract][Full Text] [Related]
3. Case report: pembrolizumab-induced Type 1 diabetes in a patient with metastatic cholangiocarcinoma.
Smith-Cohn MA; Gill D; Voorhies BN; Agarwal N; Garrido-Laguna I
Immunotherapy; 2017 Sep; 9(10):797-804. PubMed ID: 28877632
[TBL] [Abstract][Full Text] [Related]
4. Isolated adrenocorticotropic hormone deficiency and thyroiditis associated with nivolumab therapy in a patient with advanced lung adenocarcinoma: a case report and review of the literature.
Ohara N; Kobayashi M; Ohashi K; Ito R; Ikeda Y; Kawaguchi G; Yoneoka Y; Hasegawa G; Takada T
J Med Case Rep; 2019 Mar; 13(1):88. PubMed ID: 30909965
[TBL] [Abstract][Full Text] [Related]
5. Fulminant type 1 diabetes mellitus associated with pembrolizumab.
Mizab Mellah C; Sánchez Pérez M; Santos Rey MD; Hernández García M
Endocrinol Diabetes Nutr; 2017 May; 64(5):272-273. PubMed ID: 29056250
[No Abstract] [Full Text] [Related]
6. Sintilimab-Induced Autoimmune Diabetes in a Patient With the Anti-tumor Effect of Partial Regression.
Wen L; Zou X; Chen Y; Bai X; Liang T
Front Immunol; 2020; 11():2076. PubMed ID: 32973816
[TBL] [Abstract][Full Text] [Related]
7. Pembrolizumab-induced obstructive bronchiolitis in a patient with stage IV non-small-cell lung cancer.
Blanchard A; Bouchard N
Curr Oncol; 2019 Aug; 26(4):e571-e573. PubMed ID: 31548826
[TBL] [Abstract][Full Text] [Related]
8. Immune checkpoint inhibitor-induced diabetes mellitus with pembrolizumab.
Zand Irani A; Almuwais A; Gibbons H
BMJ Case Rep; 2022 Jan; 15(1):. PubMed ID: 35039353
[TBL] [Abstract][Full Text] [Related]
9. Cholestatic Liver Injury Induced by Pembrolizumab in a Patient with Lung Adenocarcinoma.
Kurokawa K; Hara M; Iwakami SI; Genda T; Iwakami N; Miyashita Y; Fujioka M; Sasaki S; Takahashi K
Intern Med; 2019; 58(22):3283-3287. PubMed ID: 31735738
[TBL] [Abstract][Full Text] [Related]
10. Radiation myelitis after pembrolizumab administration, with favorable clinical evolution and safe rechallenge: a case report and review of the literature.
Carausu M; Beddok A; Langer A; Girard N; Bidard FC; Massiani MA; Ricard D; Cabel L
J Immunother Cancer; 2019 Nov; 7(1):317. PubMed ID: 31753021
[TBL] [Abstract][Full Text] [Related]
11. Diabetic ketoacidosis induced by a single dose of pembrolizumab.
Maamari J; Yeung SJ; Chaftari PS
Am J Emerg Med; 2019 Feb; 37(2):376.e1-376.e2. PubMed ID: 30361152
[TBL] [Abstract][Full Text] [Related]
12. Case report: reinitiating pembrolizumab treatment after small bowel perforation.
Beck TN; Kudinov AE; Dulaimi E; Boumber Y
BMC Cancer; 2019 Apr; 19(1):379. PubMed ID: 31018834
[TBL] [Abstract][Full Text] [Related]
13. Development of Thyroid Carcinoma During Treatment With Pembrolizumab in a Lung Cancer Patient.
Gorospe L; García-Gómez-Muriel I; Pian-Arias HG; Gómez-Ramírez J; Rioja-Martín ME; Olmedo-García ME; Garrido-López P; Muñoz-Molina GM; Mezquita L
Ann Thorac Surg; 2020 Jun; 109(6):e397-e399. PubMed ID: 31846639
[TBL] [Abstract][Full Text] [Related]
14. Isolated neutropenia as a rare but serious adverse event secondary to immune checkpoint inhibition.
Naqash AR; Appah E; Yang LV; Muzaffar M; Marie MA; Mccallen JD; Macherla S; Liles D; Walker PR
J Immunother Cancer; 2019 Jul; 7(1):169. PubMed ID: 31277704
[TBL] [Abstract][Full Text] [Related]
15. Anti-PD-1 pembrolizumab induced autoimmune diabetes in Chinese patient: A case report.
Li S; Zhang Y; Sun Z; Hu J; Fang C
Medicine (Baltimore); 2018 Nov; 97(45):e12907. PubMed ID: 30407284
[TBL] [Abstract][Full Text] [Related]
16. Immune Checkpoint Inhibitor-Induced Diabetic Ketoacidosis: A Report of Four Cases and Literature Review.
Hong AR; Yoon JH; Kim HK; Kang HC
Front Endocrinol (Lausanne); 2020; 11():14. PubMed ID: 32047478
[TBL] [Abstract][Full Text] [Related]
17. Neuropsychiatric Immune-related Adverse Events Induced by Pembrolizumab in a Patient with Lung Adenocarcinoma and Systemic Lupus Erythematosus.
Jono M; Kinehara Y; Utsu Y; Tamura Y; Koseto M; Murakami T; Uota A; Ninomiya R; Komo S; Sumitani S; Sato B; Kasayama S; Tachibana I
Intern Med; 2020 Feb; 59(4):569-572. PubMed ID: 31666468
[TBL] [Abstract][Full Text] [Related]
18. Pericardial tamponade during pembrolizumab treatment in a patient with advanced lung adenocarcinoma: A case report and review of the literature.
Harada K; Ogasawara M; Shido A; Meno A; Oda S; Yoshida S; Yoshida S; Yoshikawa A; Ebata K; Abiko S; Kawagishi N; Sano I; Oda H; Miyagishima T
Thorac Cancer; 2020 May; 11(5):1350-1353. PubMed ID: 32181993
[TBL] [Abstract][Full Text] [Related]
19. A Severe Case of Diabetic Ketoacidosis and New-Onset Type 1 Diabetes Mellitus Associated with Anti-Glutamic Acid Decarboxylase Antibodies Following Immunotherapy with Pembrolizumab.
Kedzior SK; Jacknin G; Hudler A; Mueller SW; Kiser TH
Am J Case Rep; 2021 Jun; 22():e931702. PubMed ID: 34185763
[TBL] [Abstract][Full Text] [Related]
20. Intralymphatic histiocytosis in a patient with lung adenocarcinoma treated with pembrolizumab: a case report.
Sugano T; Seike M; Funasaka Y; Yoshida M; Takayama R; Okamura K; Nakanishi A; Tanaka T; Takeuchi S; Noro R; Minegishi Y; Kubota K; Saeki H; Gemma A
J Immunother Cancer; 2019 Feb; 7(1):59. PubMed ID: 30813943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]